The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19

July 30, 2020

Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Parexel’s Chief Commercial and Strategy Officer, talks with Paul Bridges, Worldwide Head of Regulatory and Access, and Sheela Hegde, a Partner with Parexel’s Health Advances subsidiary, about the regulatory, investing and clinical development changes that are most likely here to stay – The New Pragmatism.

Previous Article
Top 10 Myths About Working with the FDA for an Oncology Drug Approval
Top 10 Myths About Working with the FDA for an Oncology Drug Approval

Among biotech companies, a primary concern is how to establish a clinical strategy for scientific and comme...

Next Article
Making a Seamless Transition to Virtual Meetings with Health Authorities: Best Practices and Recommendations
Making a Seamless Transition to Virtual Meetings with Health Authorities: Best Practices and Recommendations

Chances are, you are reading this article in your home office, or perhaps in a corner of the dining room – ...